A new joint venture for the development and marketing of innovative biotechnology products, called IncuBIO SA, was set up in the Mariel Special Development Zone; according to an announcement made by the companies CIMAB SA (Cuban) and Neuronic Mexicana SA de CV
According to information on the website of the Ministry of Foreign Trade and Foreign Investment (Mincex), IncuBIO is designed to attract venture capital, and its shares can be acquired by future investors, in order to increase the value of products by financing clinical trials in markets of underdeveloped countries.
Among the innovative products the development and marketing covers the exclusive license of the new mixed entity, is NeuroEPO, one of the most promising assets in the portfolio of the Center for Molecular Immunology, as it is tested as a treatment for various neurodegenerative diseases, such as Alzheimer’s, Parkinson’s and Ataxia.
Details the publication of Mincex that, with the incorporation of IncuBIO, CIMAB -dedicated to the development and administration of business through its direct participation in international alliances- is a shareholder of five joint ventures located in China, Thailand, Singapore and Cuba .
For its part, Neuronic Mexicana SA de CV is responsible for the marketing of biopharmaceuticals and medical equipment.